Idorsia reports results in relation to the Axovan arbitratio

Idorsia reports results in relation to the Axovan arbitration – claim dismissed by Arbitral Tribunal


About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, state-of-the-art facilities, and a strong balance sheet – the ideal constellation to translate R&D efforts into business success.

Related Keywords

Allschwil , Switzerland General , Switzerland , Swiss , Andrewc Weiss , , Idorsia Ltd , Head Of Investor Relations Corporate Communications , Actelion Ltd , Idorsia Pharmaceuticals Ltd , Swiss Exchange , Johnson , Arbitral Tribunal , Vice President , Investor Relations , Pharmaceuticals Ltd , சுவிட்சர்லாந்து ஜநரல் , சுவிட்சர்லாந்து , சுவிஸ் , தலை ஆஃப் முதலீட்டாளர் உறவுகள் பெருநிறுவன தகவல்தொடர்புகள் , சுவிஸ் பரிமாற்றம் , ஜான்சன் , நடுவர் தீர்ப்பாயம் , துணை ப்ரெஸிடெஂட் , முதலீட்டாளர் உறவுகள் , மருந்துகள் லிமிடெட் ,

© 2025 Vimarsana